Parkinson's Disease is a prestigious open access journal dedicated to advancing the field of neurology with a special emphasis on Parkinson's disease and related movement disorders. Published by Hindawi Ltd, the journal has established itself as a vital resource since its inception in 2008, transitioning to an open access model in 2010. Featuring the ISSN 2090-8083 and E-ISSN 2042-0080, it has rapidly gained traction in the academic community, currently ranked Q2 in clinical neurology and psychiatry in the 2023 category quartiles, highlighting its significance and quality within the field. With Scopus rankings placing it in the top percentiles for neuroscience and psychiatry, it provides researchers, healthcare professionals, and students with cutting-edge research, reviews, and clinical studies. Situated in London, England, this journal encourages submissions that contribute to the understanding and management of Parkinson's disease, showcasing the latest findings and fostering collaboration among researchers worldwide.

Degenerative Neurological and Neuromuscular Disease is a distinguished academic journal published by DOVE MEDICAL PRESS LTD, focusing on the latest advancements in the field of neurology and neuromuscular disorders. With a commitment to disseminating high-quality research, the journal aims to provide a critical platform for researchers, healthcare professionals, and students to share and engage with groundbreaking studies that advance our understanding of degenerative conditions affecting the nervous system. Although the journal's impact factor and h-index are currently not available, its open access model ensures that the valuable findings published within are accessible to a global audience, thereby fostering collaboration and innovation in neurological health. The journal's address is PO BOX 300-008, Albany, Auckland 0752, New Zealand, reflecting its international relevance and commitment to advancing the field of neurology. As the understanding of neurodegenerative diseases and neuromuscular challenges continues to evolve, Degenerative Neurological and Neuromuscular Disease serves as an essential resource for anyone dedicated to improving patient outcomes and advancing scientific knowledge.

ACTA NEUROLOGICA SCANDINAVICA is a prestigious journal published by Wiley that has significantly contributed to the field of neurology and neuroscience since its inception in 1961. With a broad scope encompassing clinical and experimental research, this journal is esteemed for its rigorous peer-review process and high-quality publications. Located in the United Kingdom, it is recognized in the 2023 category quartiles as Q1 in Medicine (miscellaneous) and Q2 in both Neurology and Clinical Neurology, indicating its strong influence and relevance within the medical community. With an H-index demonstrating consistent citation impact, ACTA NEUROLOGICA SCANDINAVICA holds a Scopus rank of #86 out of 400 in Clinical Neurology, reflecting its contribution to advancing current knowledge and practice. Researchers, professionals, and students alike will find in this journal a valuable resource for the latest findings, discussions, and developments in understanding neurological disorders and treatments, furthering educational and clinical endeavors alike.

European Neurology, published by KARGER, is a distinguished journal in the field of neurology, catering to both clinical and neuroscience specialties. Since its inception in 1897 and continuing through 2024, the journal has been a vital platform for disseminating significant research findings and insights in neurology. With an ISSN of 0014-3022 and E-ISSN of 1421-9913, it ranks in the Q3 quartile in both clinical neurology and general neurology categories, reflecting its commitment to scholarly excellence while holding the 175th rank in clinical medicine and the 93rd in neuroscience, according to Scopus metrics. European Neurology facilitates a deeper understanding of neurological disorders and treatments, appealing to a diverse readership that includes researchers, clinicians, and students alike. Despite not currently offering open access, the journal’s rigorous peer-review process ensures that only high-quality research reaches its audience, making it an essential resource for those looking to stay informed in the rapidly evolving field of neurology.

CURRENT GENE THERAPY is a leading journal in the field of gene therapy, offering a platform for researchers and professionals to publish their findings related to innovative approaches in gene-based treatments. Published by Bentham Science Publishers Ltd, this journal, with its ISSN 1566-5232 and E-ISSN 1875-5631, is indexed in respected databases, enhancing its visibility and impact in the scientific community. As of 2023, it holds a commendable impact factor, with categorized quartile rankings reflecting its influence, especially in Drug Discovery (Q2), Genetics (Q3), and Molecular Medicine (Q3). Although it follows a subscription model, the journal aims to bridge the gap between laboratory research and clinical applications, attracting submissions that provide critical insights into gene therapy advancements from 2001 to 2024. The editorial scope covers various aspects of gene therapy, including experimental studies and clinical trials, underlining its commitment to fostering knowledge that addresses genetic disorders and enhances therapeutic efficacy. Whether you are a researcher, clinician, or student, CURRENT GENE THERAPY serves as an invaluable resource at the forefront of genetic research and medical innovation.

REVIEWS IN THE NEUROSCIENCES is a prestigious peer-reviewed journal published by Walter de Gruyter GmbH, specializing in the multidisciplinary field of neuroscience. With a robust history dating back to 1986 and a converged publishing timeline through to 2024, this journal serves as an essential platform for researchers and professionals who seek to explore the complexities of neuroscience in a rapidly evolving landscape. The journal is currently indexed in Scopus, boasting an impressive rank of #19 out of 113 in the General Neuroscience category, positioning it in the 83rd percentile of academic journals. It is classified within the Q2 quartile, reflecting its significant impact and contribution to the field. While not an Open Access publication, the journal offers extensive access options for institutions and individuals eager to stay informed about the latest findings and advancements in neuroscience. REVIEWS IN THE NEUROSCIENCES aims to provide comprehensive reviews covering a wide range of topics in neuroscience, fostering scholarly discussion and advancing knowledge, making it an invaluable resource for researchers, academics, and students alike.

JAMA Neurology is a leading peer-reviewed journal published by the American Medical Association, focused on advancing the understanding and treatment of neurological disorders. With an impressive impact factor and ranked in the 99th percentile among clinical neurology journals, this publication is recognized as Q1 in its category for 2023, highlighting its significance in the field. Since its inception, the journal has provided a platform for high-quality research, clinical trials, and reviews that inform both clinicians and researchers. Operating from its headquarters in Chicago, Illinois, JAMA Neurology offers rich insights into the latest advancements in neurology, featuring articles that span a wide range of topics including neurodegenerative diseases, stroke, epilepsy, and neurocritical care. Researchers and professionals are encouraged to access the journal’s content freely, as it employs open access options to promote the dissemination of critical knowledge. As a critical resource in the field of neurology, JAMA Neurology is essential for anyone involved in this dynamic and rapidly evolving specialty.

EUROPEAN JOURNAL OF NEUROLOGY, published by WILEY, stands as a leading platform for the dissemination of innovative research and clinical developments in the field of neurology. With a robust impact factor and prestigious rankings, including being positioned as Q1 in both Neurology and Clinical Neurology categories, the journal plays a pivotal role in shaping neurological sciences from 1994 to 2024. Its Scopus rank highlights its importance, being in the 88th percentile for clinical neurology and 87th percentile for neuroscience. Located in the United Kingdom, the journal thrives as a vital resource for researchers, clinicians, and students dedicated to improving neurological health outcomes. Although it does not offer Open Access, its subscription-based model ensures high-quality peer-reviewed articles are accessible to a global audience, reflecting the continuous pursuit of excellence in neurological research and patient care.

EXPERIMENTAL NEUROLOGY is a premier academic journal published by Academic Press Inc, Elsevier Science, focusing on advancements in the fields of Developmental Neuroscience and Neurology. With an impressive Impact Factor and ranked in the Q1 quartile of both categories—positioning it among the top-tier journals—this publication has established itself as a vital resource for researchers, clinicians, and students alike. Since its inception in 1959, it has fostered the dissemination of cutting-edge research and innovative approaches to understanding neurological function and related disorders. While EXPERIMENTAL NEUROLOGY currently operates under a subscription access model, its rich archives and ongoing contributions to the field continue to inspire and inform the next generation of neurobiologists. The journal also boasts a high ranking in Scopus, placing fourth in Developmental Neuroscience and twentieth in Neurology, indicating its robust influence and scholarly significance. For those committed to advancing knowledge in these critical areas, EXPERIMENTAL NEUROLOGY is an indispensable platform for inquiry and discovery.

CELL TRANSPLANTATION is a premier multidisciplinary journal dedicated to advancing the field of regenerative medicine and transplantation, published by SAGE PUBLICATIONS INC. Since its initiation in 1992 and embracing an open-access model since 2017, the journal aims to disseminate high-quality research that covers both clinical and experimental studies on cell and tissue transplantation. With a notable impact reflected in its 2023 Q2 ranking in Biomedical Engineering and significant standings in Cell Biology and Transplantation, CELL TRANSPLANTATION serves as a vital resource for researchers, practitioners, and students alike. The journal's commitment to fostering innovation is evident in its diverse contributions that address the complexities of tissue engineering, immunology, and regenerative therapies, inviting readers to engage with cutting-edge science that is poised to transform medical practices and improve patient outcomes. The journal's insightful articles and research findings make it a crucial platform for knowledge exchange within the vibrant scientific community.